Skip to Content

Levofloxacin Side Effects

In Summary

More frequently reported side effects include: insomnia and diarrhea. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to levofloxacin: oral solution, oral syrup, oral tablet

Other dosage forms:

In addition to its needed effects, some unwanted effects may be caused by levofloxacin. In the event that any of these side effects do occur, they may require medical attention.

Severity: Major

You should check with your doctor immediately if any of these side effects occur when taking levofloxacin:

More common:
  • Diarrhea
  • Abdominal or stomach cramps or pain (severe)
  • agitation
  • blisters
  • confusion
  • diarrhea (watery and severe) which may also be bloody
  • feeling that others can hear your thoughts or control your behavior
  • fever
  • pain, inflammation, or swelling in the calves of the legs, shoulders, or hands
  • redness and swelling of the skin
  • seeing, hearing, or feeling things that are not there
  • sensation of burning on the skin
  • severe mood or mental changes
  • skin rash, itching, or redness
  • trembling
  • unusual behavior
Incidence not known:
  • Black, tarry stools
  • blurred vision
  • burning, numbness, tingling, or painful sensations
  • convulsions
  • cough
  • dark-colored urine
  • difficulty with breathing
  • difficulty with chewing, talking, or swallowing
  • drooping eyelids
  • fast or irregular heartbeat
  • general body swelling
  • hives
  • hoarseness
  • joint or muscle pain
  • muscle cramps, spasms, pain, or stiffness
  • peeling or loosening of the skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • severe dizziness
  • severe tiredness
  • tightness in the chest
  • unsteadiness or awkwardness
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vision changes
  • voice changes
  • weakness in the arms, hands, legs, or feet

Severity: Minor

Some of the side effects that can occur with levofloxacin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common:
  • Abdominal or stomach pain or discomfort
  • change in taste
  • constipation
  • dizziness
  • drowsiness
  • headache
  • lightheadedness
  • nausea
  • nervousness
  • trouble sleeping
  • vaginal itching and discharge
  • vomiting
Incidence not known:
  • Feeling faint
  • feeling of warmth or heat
  • flushing or redness of the skin, especially on the face and neck
  • sweating

For Healthcare Professionals

Applies to levofloxacin: compounding powder, intravenous solution, oral solution, oral tablet


The most frequently reported side effects included nausea, headache, diarrhea, insomnia, constipation, and dizziness. Therapy was discontinued due to adverse effects in 4.3% of patients overall (3.8% treated with 250 mg and 500 mg doses; 5.4% treated with 750 mg dose). The most common side effects leading to discontinuation were gastrointestinal (primarily nausea, vomiting), dizziness, and headache.[Ref]


During one study, Clostridium difficile diarrhea occurred in 11 of 490 study patients (2.2%) receiving levofloxacin.[Ref]

Common (1% to 10%): Nausea (7%), diarrhea (5%), constipation (3%), abdominal pain (2%), dyspepsia (2%), vomiting (2%)
Uncommon (0.1% to 1%): Anorexia, gastroenteritis, pancreatitis, glossitis, gastritis, esophagitis, stomatitis, pseudomembranous/Clostridium difficile colitis
Frequency not reported: Dry mouth, dysphagia, flatulence, gastrointestinal hemorrhage, tongue edema, gastroesophageal reflux, melena, taste perversion, intestinal perforation, intestinal obstruction[Ref]

Nervous system

Common (1% to 10%): Headache (6%), dizziness (3%)
Uncommon (0.1% to 1%): Convulsions, hyperkinesias, hypertonia, paresthesia, somnolence, tremor, vertigo, abnormal gait, syncope
Rare (less than 0.1%): Sensory or sensorimotor axonal polyneuropathy (resulting in paresthesias, hypoesthesias, dysesthesias, weakness)
Frequency not reported: Abnormal coordination, coma, hypoesthesia, involuntary muscle contractions, hyperesthesia, paralysis, speech disorder, stupor, encephalopathy, leg cramps, ataxia, migraine, seizures, intracranial hypertension
Postmarketing reports: Abnormal electroencephalogram (EEG), exacerbation of myasthenia gravis, anosmia, ageusia, parosmia, dysgeusia, encephalopathy (isolated reports), dysphonia, pseudotumor cerebri, hypoacusis, tinnitus, peripheral neuropathy (may be irreversible)[Ref]

One survey reported 33 cases of peripheral neuropathy associated with levofloxacin, ranging in severity from mild and reversible to severe and persistent. In one case, a 51-year-old female developed "electrical" sensations, numbness, allodynia, multiple severe tendinitis, partial tendon rupture, impaired memory, confusion, and impaired concentration, with some symptoms persisting after 1 year.[Ref]


Common (1% to 10%): Insomnia (4%)
Uncommon (0.1% to 1%): Abnormal dreaming, agitation, anxiety, confusion, depression, hallucination, nightmare, sleep disorder
Frequency not reported: Paroniria, nervousness, aggressive reaction, delirium, emotional lability, impaired concentration, manic reaction, mental deficiency, toxic psychoses, withdrawal syndrome
Postmarketing reports: Psychosis, paranoia, suicide attempt (isolated reports), suicidal ideation (isolated reports)[Ref]


A 78-year-old female developed toxic epidermal necrolysis 2 days after parenteral levofloxacin therapy. The rash initially manifested as an erythematous rash, blistering, and mucosal sloughing but progressed to exfoliation involving three-quarters of the patient's body surface area including mucosa. A positive Nikolsky sign was noted.

A 15-year-old male developed fatal toxic epidermal necrolysis taking levofloxacin for 9 days. The rash progressed over 40 hours to involve 80% of his body surface area with a positive Nikolsky sign and involvement of the eyes and oral, nasal, and perianal mucosa.[Ref]

Common (1% to 10%): Rash (2%), pruritus (1%)
Uncommon (0.1% to 1%): Urticaria
Frequency not reported: Dry skin, increased sweating, skin disorder, skin exfoliation, skin ulceration, erythematous rash, alopecia, maculopapular rash, erythema nodosum, eczema
Postmarketing reports: Photosensitivity/phototoxicity reaction, bullous eruptions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme), leukocytoclastic vasculitis[Ref]


Achilles tendon rupture occurred in 4 of 489 study patients (3217 treatment days) after 1 to 10 days of levofloxacin treatment.

Severe rhabdomyolysis occurred in a 77-year-old female after 6 days of oral levofloxacin therapy. She developed acute renal failure (serum creatinine 678 micromole/L), hyperkalemia (6.8 micromole/L), anuria, elevated creatine kinase (30,400 international units/L), myoglobinemia (86,000 mcg/L), and acute hepatic cytolysis (SGOT 555 international units/L, SGPT 249 international units/L). The fluid/electrolyte disorders and creatine kinase and myoglobin levels improved with hemodialysis; however, the patient died of a myocardial infarction and respiratory failure after 13 days.[Ref]

Uncommon (0.1% to 1%): Arthralgia, myalgia, skeletal pain, tendinitis
Frequency not reported: Arthritis, arthrosis, pathological fracture, osteomyelitis, synovitis, muscle weakness, tendon disorder
Postmarketing reports: Tendon rupture, muscle injury (including rupture), increased muscle enzymes, rhabdomyolysis[Ref]


Levofloxacin was associated with 13 cases of torsade de pointes reported to the FDA between 1996 and 2001.

The risk of arrhythmias may be lessened by avoiding use in patients with hypokalemia, significant bradycardia, or concurrent treatment with Class IA or III antiarrhythmic agents.

An 88-year-old woman developed a prolonged QTc interval while being treated with levofloxacin 500 mg once a day. The QTc interval increased from 450 msec to 577 msec by the fourth day of treatment. Levofloxacin was discontinued after the patient experienced runs of ventricular tachycardia. The QTc interval then decreased to 437 msec two days after discontinuing levofloxacin.

A 65-year-old woman with hypokalemia (2.8 mEq/L), hypomagnesemia (1.5 mEq/L), and renal insufficiency (Scr 7.7 mg/dL, BUN 34 mg/dL) developed a QTc interval of 605 ms (baseline 435-485 ms), several episodes of torsade de pointes, and cardiac arrest after 3 days of levofloxacin 250 mg/day IV. The QTc interval decreased to 399 ms and no further arrhythmias occurred after discontinuation of levofloxacin and electrolyte replacement.

Hypotension has been associated with rapid or bolus IV infusion.[Ref]

Uncommon (0.1% to 1%): Cardiac arrest, palpitation, phlebitis, ventricular arrhythmia, ventricular tachycardia
Frequency not reported: Angina pectoris, arrhythmia, atrial fibrillation, bradycardia, cardiac failure, cerebrovascular disorder, circulatory failure, coronary thrombosis, heart block, hypertension, aggravated hypertension, hypotension, myocardial infarction, postural hypotension, purpura, supraventricular tachycardia, tachycardia, deep thrombophlebitis, vasculitis, ventricular fibrillation
Postmarketing reports: Vasodilation, QT interval prolongation/prolonged electrocardiogram QT, tachycardia, torsade de pointes[Ref]


Common (1% to 10%): Chest pain (1%), edema (1%), moniliasis (1%)
Frequency not reported: Asthenia, fever, malaise, rigors, substernal chest pain, ascites, changed temperature sensation, ear disorder (unspecified), enlarged abdomen, hot flashes, gangrene, influenza-like symptoms, leg pain, multiple organ failure, earache, abscess, herpes simplex, bacterial infection, viral infection, otitis media, sepsis, pain, fatigue, face edema, flushing, back pain, aggravated condition, fungal infection
Postmarketing reports: Multi-organ failure, pyrexia[Ref]


Uncommon (0.1% to 1%): Abnormal hepatic function, increased hepatic enzymes, increased alkaline phosphatase
Frequency not reported: Acute hepatocellular injury, cholecystitis, cholelithiasis, hepatic coma, hepatic necrosis, bilirubinemia
Postmarketing reports: Severe hepatotoxicity (including acute hepatitis and fatal events), hepatic failure (including fatal cases), hepatitis, jaundice[Ref]

A 74-year-old female developed hepatotoxicity and significant increases in AST (4962 units/L), ALT (7071 units/L), alkaline phosphatase (90 units/L), and total bilirubin (2.5 mg/dL) after starting levofloxacin therapy. Levels returned to normal within a week after discontinuation.

Severe hepatotoxicity usually occurred within 14 days (most within 6 days) after starting levofloxacin and most cases were not associated with hypersensitivity. The majority of fatal hepatotoxicity cases occurred in patients 65 years or older and most were not associated with hypersensitivity.[Ref]


Uncommon (0.1% to 1%): Allergic reaction
Postmarketing reports: Hypersensitivity reactions (sometimes fatal and including anaphylactic/anaphylactoid reactions, anaphylactic shock, serum sickness, angioneurotic edema)[Ref]


Common (1% to 10%): Dyspnea (1%)
Uncommon (0.1% to 1%): Epistaxis
Frequency not reported: Rhinitis, sinusitis, pharyngitis, bronchitis, chronic obstructive airway disease, laryngitis, pleurisy, pneumonitis, upper respiratory tract infection, asthma, cough, hemoptysis, hiccough, hypoxia, pleural effusion, pulmonary embolism, respiratory insufficiency, airway obstruction, ARDS, aspiration, bronchospasm, emphysema, pneumonia, pneumothorax, pulmonary collapse, pulmonary edema, respiratory depression, respiratory disorder
Postmarketing reports: Allergic pneumonitis (isolated reports)[Ref]


Uncommon (0.1% to 1%): Anemia, granulocytopenia, thrombocytopenia
Frequency not reported: Decreased lymphocytes, abnormal WBCs (unspecified), abnormal platelets, agranulocytosis, hematoma, leukocytosis, lymphadenopathy, decreased prothrombin, purpura, thrombocythemia
Postmarketing reports: Hemolytic anemia, eosinophilia, leukopenia, pancytopenia, aplastic anemia, prothrombin time prolonged, international normalized ratio prolonged[Ref]


Uncommon (0.1% to 1%): Abnormal renal function, acute renal failure
Frequency not reported: Renal calculi, allergic interstitial nephritis
Postmarketing reports: Interstitial nephritis[Ref]

A 73-year-old male developed vasculitis and acute renal failure within 3 days of initiating oral levofloxacin. Symptoms included significantly decreased urine output (0.5 L/d to 0.7 L/d), palpable purpura, erythematous skin lesions, and increased serum creatinine (6.4 mg/dL) and BUN (190 mg/dL). The condition resolved within 4 weeks after discontinuation of levofloxacin. Due to the possibility that this may have been an allergic reaction, rechallenge was not attempted.[Ref]


A 79-year-old male with type 2 diabetes mellitus developed severe hypoglycemia (blood glucose 6 mg/dL) and became unresponsive 6 hours after receiving one dose of intravenous levofloxacin 250 mg. Blood glucose levels subsequently ranged between 40 to 159 mg/dL with dextrose doses and infusions; however, he did not regain consciousness and expired 2 days later.[Ref]

Uncommon (0.1% to 1%): Hyperglycemia, hyperkalemia, hypoglycemia
Frequency not reported: Decreased blood glucose, hypomagnesemia, thirst, aggravated diabetes mellitus, dehydration, hypokalemia, gout, hypernatremia, hypophosphatemia, increased lactate dehydrogenase, weight decrease, fluid overload, hyponatremia, increased nonprotein nitrogen, acidosis, symptomatic hypoglycemia, elevated serum triglycerides, elevated serum cholesterol, electrolyte abnormalities[Ref]


Common (1% to 10%): Vaginitis (1%)
Uncommon (0.1% to 1%): Genital moniliasis
Frequency not reported: Dysmenorrhea, hematuria, dysuria, oliguria, urinary incontinence, urinary retention, leukorrhea, genital pruritus, ejaculation failure, impotence, albuminuria, candiduria, crystalluria, cylindruria, vaginal candidiasis, urinary tract infection[Ref]


Frequency not reported: Ophthalmologic abnormalities (including cataracts, multiple punctate lenticular opacities), abnormal vision, eye pain, nystagmus, conjunctivitis
Postmarketing reports: Vision disturbance (including diplopia), reduced visual acuity, blurred vision, scotomata[Ref]


Frequency not reported: Carcinoma[Ref]


Common (1% to 10%): Injection site reactions (1%)
Frequency not reported: Injection site pain, injection site inflammation[Ref]


1. Croom KF, Goa KL "Levofloxacin: A Review of its Use in the Treatment of Bacterial Infections in the United States." Drugs 63 (2003): 2769-2802

2. "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.

3. Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001): 32-7

4. Yagawa K "Latest industry information on the safety profile of levofloxacin in Japan." Chemotherapy 47 Suppl 3 (2001): 38-43

5. Sydnor TA, Kopp EJ, Anthony KE, LoCoco JM, Kim SS, Fowler CL "Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults." Ann Allergy Asthma Immunol 80 (1998): 357-62

6. Anderson VR, Perry CM "Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection." Drugs 68 (2008): 535-65

7. Klimberg IW, Cox CE, Fowler CL, King W, Kim SS, CalleryDAmico S "A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection." Urology 51 (1998): 610-5

8. Chien SC, Wong FA, Fowler CL, CalleryDAmico SV, Williams RR, Nayak R, Chow AT "Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers." Antimicrob Agents Chemother 42 (1998): 885-8

9. Gopal Rao G, Mahankali Rao CS, Starke I "Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy." J Antimicrob Chemother 51 (2003): 697-701

10. Marra F, Marra CA, Moadebi S, et al. "Levofloxacin treatment of active tuberculosis and the risk of adverse events." Chest 128 (2005): 1406-13

11. Sato A, Ogawa H, Iwata M, Ono T, Yasuda K, Nagayama M, Shirai T, Shirai M, Ida M, Suda T, et al "Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections." Drugs 49(suppl 2 (1995): 428-9

12. Adelglass J, Jones TM, Ruoff G, et al. "A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of bacterial sinusitis." Pharmacotherapy 18 (1998): 1255-63

13. Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC, Bartlett JA "Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection." Antimicrob Agents Chemother 38 (1994): 799-804

14. Shams WE, Evans ME "Guide to Selection of Fluoroquinolones in Patients with Lower Respiratory Tract Infections." Drugs 65 (2005): 949-991

15. Cohen JS "Peripheral neuropathy associated with fluoroquinolones." Ann Pharmacother 35 (2001): 1540-7

16. Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC "Seizures associated with levofloxacin: case presentation and literature review." Eur J Clin Pharmacol 65 (2009): 959-62

17. Kawai T "Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections." Drugs 49(suppl 2 (1995): 416-7

18. Bird SB, Orr PG, Mazzola JL, Brush DE, Boyer EW "Levofloxacin-Related Seizure Activity in a Patient With Alzheimer's Disease: Assessment of Potential Risk Factors." J Clin Psychopharmacol 25 (2005): 287-288

19. Corral De La Calle M, Martin Diaz MA, Flores CR, Vidaurrazaga C "Acute localized exanthematous pustulosis secondary to levofloxacin." Br J Dermatol 152 (2005): 1076-7

20. Boccumini LE, Fowler CL, Campbell TA, Puertolas LF, Kaidbey KH "Photoreaction potential of orally administered levofloxacin in healthy subjects." Ann Pharmacother 34 (2000): 453-8

21. Maunz G, Conzett T, Zimmerli W "Cutaneous vasculitis associated with fluoroquinolones." Infection 37 (2009): 466-8

22. Dawe RS, Ibbotson SH, Sanderson JB, Thomson EM, Ferguson J "A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity." Br J Dermatol 149 (2003): 1232-41

23. Fleisch E, Hartmann K, Kuhn M "Fluouroquinolone-induced tendinopathy: Also occurring with levofloxacin." Infection 28 (2000): 256-7

24. Haddow LJ, Chandra Sekhar M, Hajela V, Gopal Rao G "Spontaneous Achilles tendon rupture in patients treated with levofloxacin." J Antimicrob Chemother 51 (2003): 747-8

25. Hsiao SH, Chang CM, Tsao CJ, Lee YY, Hsu MY, Wu TJ "Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy." Ann Pharmacother 39 (2004): 146-9

26. Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410

27. Mathis AS, Chan V, Gryszkiewicz M, Adamson RT, Friedman GS "Levofloxacin-Associated Achilles Tendon Rupture." Ann Pharmacother 37 (2003): 1014-1017

28. Lewis JR, Gums JG, Dickensheets DL "Levofloxacin-induced bilateral achilles tendonitis." Ann Pharmacother 33 (1999): 792-5

29. Vyas H, Krishnaswamy G "Images in clinical medicine. Quinolone-associated rupture of the Achilles' tendon." N Engl J Med 357 (2007): 2067

30. Petitjeans F, Nadaud J, Perez JP, et al. "A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin." Eur J Clin Pharmacol 59 (2003): 779-80

31. Briasoulis A, Agarwal V, Pierce WJ "QT Prolongation and Torsade de Pointes Induced by Fluoroquinolones: Infrequent Side Effects from Commonly Used Medications." Cardiology 120 (2011): 103-110

32. Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B "Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?" South Med J 99 (2006): 52-6

33. Berger RE "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." J Urol 174 (2005): 165

34. Amankwa K, Krishnan SC, Tisdale JE "Torsades de pointes associated with fluoroquinolones: Importance of concomitant risk factors." Clin Pharmacol Ther 75 (2004): 242-7

35. Abo-Salem E, Nugent K, Chance W "Antibiotic-induced cardiac arrhythmia in elderly patients." J Am Geriatr Soc 59 (2011): 1747-9

36. Ramakrishnan K, Scheid DC "Diagnosis and management of acute pyelonephritis in adults." Am Fam Physician 71 (2005): 933-42

37. Owens RC Jr, Nolin TD "Antimicrobial-Associated QT Interval Prolongation: Pointes of Interest." Clin Infect Dis 43 (2006): 1603-1611

38. Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72

39. Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001): 46-7

40. Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999): 528-9

41. Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S "Fluoroquinolones and the risk of serious arrhythmia: a population-based study." Clin Infect Dis 55 (2012): 1457-65

42. Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72

43. Coban S, Ceydilek B, Ekiz F, Erden E, Soykan I "Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection." Ann Pharmacother 39 (2005): 1737-40

44. Karim A, Ahmed S, Rossoff LJ, Siddiqui RK, Steinberg HN "Possible levofloxacin-induced acute hepatocellular injury in a patient with chronic obstructive lung disease." Clin Infect Dis 33 (2001): 2088-90

45. Paterson JM, Mamdani MM, Manno M, Juurlink DN "Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study." CMAJ 184 (2012): 1565-70

46. Solomon NM, Mokrzycki MH "Levofloxacin-induced allergic interstitial nephritis." Clin Nephrol 54 (2000): 356

47. Islam AS, Rahman MS "Levofloxacin-induced fatal toxic epidermal necrolysis." Ann Pharmacother 39 (2005): 1136-7

48. Digwood-Lettieri S, Reilly KJ, Haith LR Jr, et al. "Levofloxacin-induced toxic epidermal necrolysis in an elderly patient." Pharmacotherapy 22 (2002): 789-93

49. Oh YR, Carr-Lopez SM, Probasco JM, Crawley PG "Levofloxacin-induced autoimmune hemolytic anemia." Ann Pharmacother 37 (2003): 1010-3

50. Famularo G, De Simone C "Nephrotoxicity and purpura associated with levofloxacin." Ann Pharmacother 36 (2002): 1380-2

51. Singh N, Jacob JJ "Levofloxacin and hypoglycemia." Clin Infect Dis 46 (2008): 1127

52. Laplante KL, Mersfelder TL, Ward KE, Quilliam BJ "Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting." Pharmacotherapy 28 (2008): 82-9

53. Lodise T, Graves J, Miller C, Mohr JF, Lomaestro B, Smith RP "Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients." Pharmacotherapy 27 (2007): 1498-505

54. Kelesidis T, Canseco E "Levofloxacin-induced hypoglycemia: a rare but life-threatening side effect of a widely used antibiotic." Am J Med 122 (2009): e3-4

55. Graumlich JF, Habis S, Avelino RR, et al. "Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study." Pharmacotherapy 25 (2005): 1296-302

56. Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010): e5-6

57. Micheli L, Sbrilli M, Nencini C "Severe hypoglycemia associated with levofloxacin in Type 2 diabetic patients receiving polytherapy: two case reports." Int J Clin Pharmacol Ther 50 (2012): 302-6

58. Gibert AE, Porta FS "Hypoglycemia and levofloxacin: a case report." Clin Infect Dis 46 (2008): 1126-7

59. Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004): 1807-12

Not all side effects for levofloxacin may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.